Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes

Xiang Guang-da1 site in 1 country200 target enrollmentNovember 2013

ConditionsAcute Kidney Injury The Changes of Plasma Creatinine The Changes of Plasma Free Radicals The Changes of Endothelium-dependent Arterial Dilation

InterventionsAlpha lipoic acid

DrugsAlpha lipoic acid

Overview

Phase: Phase 4
Intervention: Alpha lipoic acid
Conditions: Acute Kidney Injury
Sponsor: Xiang Guang-da
Enrollment: 200
Locations: 1
Primary Endpoint: The changes of endothelium-dependent arterial dilation before and after contrast administrated
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Contrast-induced acute kidney injury (CIAKI) is a major complication with adverse outcomes after contrast media injection. Although the risk of developing CIAKI is low in patients with normal renal function, it is dramatically higher in patients with conditions such as diabetes mellitus (DM) or chronic kidney disease (CKD). More recently, our data showed that contrast agents can induce endothelial dysfunction partially via free radicals in diabetes. Therefore, strategies to prevent CIAKI and endothelial dysfunction in DM patients with CKD are urgently needed. Alpha-lipoic acid and its reduced form, dihydrolipoate, are potent antioxidants. We hypothesized that alpha lipoic acid can prevent the contrast-induced acute kidney injury and endothelial dysfunction in type 2 diabetes.

Registry

clinicaltrials.gov

Start Date

November 2013

End Date

June 2014

Last Updated

12 years ago

Study Type

Interventional

Study Design

Parallel